The horrors of the second wave that ravaged the nation acted as an eye-opener for a lot of Indians and highlighted the importance of taking the coronavirus vaccine as soon as possible. However, with the opening of vaccination for all adults in May 2021, India experienced a steep rise in demand, which was barely met by the suppliers. This mounted to a big challenge for the policymakers and an interesting study for the economists. We saw that during the past few months, actions were taken by the centre & state governments in conjunction with domestic and international vaccine producers to satiate this demand.
In this interview with Dr. Anil Kumar Angrish, we will look at these very steps and measures from an economic point of view to understand the market dynamics of the coronavirus vaccine in India and the role of foreign pharmaceutical giants.
